Piroxicam (DB00554): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, first introduced by Pfizer in 1980 under the brand name Feldene.[1] As a small molecule therapeutic, it functions through the non-selective inhibition of the cyclooxygenase (COX) enzymes, COX-1 and COX-2, thereby blocking the synthesis of prostaglandins that mediate pain, inflammation, and fever.[1] Its primary clinical applications are in the symptomatic management of chronic inflammatory conditions, most notably osteoarthritis and rheumatoid arthritis.[4]

The pharmacological profile of piroxicam is distinguished by an exceptionally long elimination half-life, averaging approximately 50 hours.[6] This characteristic allows for the convenience of a once-daily dosing regimen, a significant advantage at the time of its introduction. However, this prolonged duration of action is also a primary contributor to its significant safety concerns. The sustained inhibition of COX-1, an enzyme crucial for gastrointestinal mucosal protection, coupled with its long half-life, elevates the risk of severe gastrointestinal adverse events. Furthermore, its metabolic clearance is almost entirely dependent on the highly polymorphic cytochrome P450 enzyme, CYP2C9, predisposing a subset of the population with reduced enzyme function ("poor metabolizers") to drug accumulation and a markedly increased risk of toxicity.[8]

Reflecting these risks, piroxicam carries two U.S. Food and Drug Administration (FDA) Black Box Warnings, the agency's most stringent advisory, for the increased risk of serious cardiovascular thrombotic events (myocardial infarction, stroke) and severe, potentially fatal gastrointestinal bleeding, ulceration, and perforation.[7] In response to post-marketing surveillance and epidemiological data suggesting a higher risk profile compared to other NSAIDs, the European Medicines Agency (EMA) has taken a more restrictive stance. The EMA has limited its indications to second-line therapy for chronic arthritis, removed its approval for acute pain conditions, and recommended that its initiation be restricted to specialists.[1]

Consequently, piroxicam's role in modern medicine has evolved. While recognized as an effective anti-inflammatory agent, its use is tempered by a well-documented and comparatively unfavorable risk-benefit profile. Its application requires careful patient selection, a thorough assessment of cardiovascular and gastrointestinal risk factors, and adherence to the principle of using the lowest effective dose for the shortest possible duration.

Chemical Identity and Physicochemical Properties

The precise identification and characterization of a pharmaceutical agent's chemical and physical properties are fundamental to understanding its behavior both in vitro and in vivo. Piroxicam is a well-defined small molecule with a unique structure that dictates its classification and pharmacological activity.

Systematic Identification

Piroxicam is recognized globally by a consistent set of chemical and database identifiers. Its International Union of Pure and Applied Chemistry (IUPAC) name is 4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide.[1] The Chemical Abstracts Service (CAS) has assigned it the registry number 36322-90-4, which is universally used in scientific literature and regulatory documents.[1] Its unique DrugBank Accession Number is DB00554.[1] Table 1 provides a consolidated list of its key identifiers and properties for reference.

Molecular Structure and Composition

Piroxicam's molecular formula is C15​H13​N3​O4​S, corresponding to a molar mass of 331.35 g·mol⁻¹.[1] Its structure is distinct from many other NSAID classes, such as the propionic acid derivatives (e.g., ibuprofen). The core of the piroxicam molecule is a fused benzothiazine ring system, which consists of a benzene ring fused to a thiazine ring containing both sulfur and nitrogen atoms. A key feature within this system is a sultam, which is a cyclic sulfonamide.[1]

Attached to this core are several functional groups that determine its chemical behavior and biological activity:

• A carboxamide group (−CONH−) links the benzothiazine core to a pyridinyl group.
• A pyridinyl group (a six-membered aromatic ring containing one nitrogen atom) is attached to the carboxamide nitrogen.
• A hydroxyl group (−OH) at the 4-position of the benzothiazine ring is responsible for the molecule's acidic properties.
• A methyl group (−CH3​) is attached to the nitrogen atom within the thiazine ring.[14]

This unique arrangement classifies piroxicam as an "oxicam" and an "enolic acid." Unlike NSAIDs that derive their acidity from a carboxylic acid moiety, piroxicam's acidity stems from the enolic 4-hydroxy substituent.[4] This structural feature is a defining characteristic of the oxicam class, which also includes drugs like meloxicam and tenoxicam.[1]

Physical and Chemical Characteristics

In its solid state, piroxicam appears as a white crystalline solid.[7] Its solubility is limited; it is sparingly soluble in water, dilute acids, and most organic solvents. It demonstrates slight solubility in alcohols and in aqueous alkaline solutions, a property consistent with its acidic nature.[7] The molecule exhibits tautomerism, existing predominantly as an alkenol tautomer in organic solvents and as a zwitterionic form in aqueous environments.[1]

The molecule has two ionizable protons, giving it distinct acid-base properties. The 4-hydroxy proton is weakly acidic, with a reported pKa of 5.1 or 6.3, while the pyridyl nitrogen is weakly basic, with a pKa of 1.8.[7] Its experimentally determined melting point is in the range of 198–200 °C.[13]

Table 1: Key Chemical and Physical Identifiers for Piroxicam

Identifier Type	Value	Source(s)
Common Name	Piroxicam	1
IUPAC Name	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	1
CAS Number	36322-90-4	1
DrugBank ID	DB00554	1
Molecular Formula	C15​H13​N3​O4​S	1
Molar Mass	331.35 g·mol⁻¹	1
SMILES	CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3	1
InChIKey	QYSPLQLAKJAUJT-UHFFFAOYSA-N	1
Physical Description	White crystalline solid	7
Melting Point	198–200 °C	13
pKa	5.1 (acidic proton), 1.8 (basic nitrogen)	7
Solubility in Water	Sparingly soluble (e.g., 23 mg/L at 22 °C)	7

Pharmacology and Mechanism of Action

Piroxicam exerts its therapeutic effects through a well-established pharmacological pathway common to its drug class, with specific characteristics that influence its clinical profile.

Therapeutic Classification

Piroxicam is classified as a non-steroidal anti-inflammatory drug (NSAID).[1] It belongs to the oxicam chemical family, a distinct subgroup of NSAIDs characterized as enolic acids.[4] As an NSAID, it exhibits a triad of therapeutic activities: anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing).[1]

Primary Mechanism of Action

The principal mechanism of action for piroxicam, like other traditional NSAIDs, is the inhibition of prostaglandin synthesis.[1] It achieves this by binding to and inhibiting the activity of the cyclooxygenase (COX) enzymes, officially known as Prostaglandin G/H synthase.[1] These enzymes are responsible for the rate-limiting step in the conversion of arachidonic acid, a fatty acid released from cell membranes, into prostaglandin precursors such as prostaglandin H2 (

PGH2​).[2] By blocking this enzymatic step, piroxicam effectively reduces the production of various downstream prostaglandins that are potent mediators of inflammation, pain, and fever.[1]

Pharmacodynamics and Molecular Targets

Piroxicam's molecular targets are the two primary isoforms of the COX enzyme: COX-1 and COX-2.[3] Its clinical effects and side effect profile are a direct consequence of its interaction with both isoforms.

• COX-1 (Prostaglandin G/H synthase 1): This isoform is constitutively expressed in many tissues and is responsible for "housekeeping" functions. In the gastric mucosa, COX-1 produces prostaglandins that maintain mucosal blood flow and stimulate the production of protective mucus and bicarbonate. In platelets, it synthesizes thromboxane A2 (TXA2​), which promotes platelet aggregation and vasoconstriction.[3]
• COX-2 (Prostaglandin G/H synthase 2): This isoform is typically absent or expressed at low levels in most tissues but is rapidly induced at sites of injury or inflammation by cytokines and other inflammatory stimuli. The prostaglandins produced by COX-2 are major contributors to the classic signs of inflammation: pain, swelling, redness, and heat.[3]

Piroxicam is functionally classified as a non-selective COX inhibitor, meaning it inhibits both COX-1 and COX-2 at therapeutic concentrations.[1] Its desired anti-inflammatory and analgesic effects are primarily mediated through the inhibition of COX-2. Conversely, its most common and serious adverse effects, particularly gastrointestinal toxicity, are a direct result of its concurrent inhibition of the protective COX-1 enzyme in the gastric lining.[3]

While the clinical classification is "non-selective," some biochemical data suggest a more nuanced interaction. One source reports piroxicam as a highly selective inhibitor of COX-1, with a ratio of half-maximal inhibitory concentrations (IC50​) for COX-2/COX-1 of approximately 600.[19] This indicates that a 600-fold higher concentration of the drug is required to inhibit 50% of COX-2 activity compared to COX-1 activity. This strong biochemical preference for COX-1 does not preclude significant COX-2 inhibition at clinically relevant plasma concentrations, but it provides a compelling mechanistic explanation for why piroxicam has a particularly high risk of gastrointestinal complications even when compared to other non-selective NSAIDs. The term "non-selective" in the clinical context serves to differentiate it from COX-2 selective inhibitors (coxibs), but its potent and preferential inhibition of COX-1 is a key determinant of its risk profile.

Secondary Mechanisms

In addition to its primary role as a COX inhibitor, piroxicam may exert anti-inflammatory effects through secondary mechanisms. It has been shown to inhibit the activation and migration of neutrophils, a type of white blood cell, into sites of inflammation.[2] By impeding the function of these key inflammatory cells, piroxicam may further contribute to the resolution of inflammation beyond the simple reduction of prostaglandins.

Pharmacokinetic Profile: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of piroxicam—how the body absorbs, distributes, metabolizes, and excretes the drug—is central to its clinical use, defining its dosing schedule, time to therapeutic effect, and, most critically, its distinct safety profile. Its exceptionally long half-life is its most defining characteristic.

Absorption

Following oral administration, piroxicam is well and readily absorbed from the gastrointestinal tract.[3] Plasma concentrations of the drug are proportional to the dose administered, with peak levels generally achieved within three to five hours post-ingestion.[7] The administration of piroxicam with food or antacids has been shown to slow the rate of absorption, slightly delaying the time to peak concentration, but it does not significantly alter the overall extent of absorption or its bioavailability.[6] In some markets, a formulation with betadex is available, which is designed to facilitate a more rapid absorption from the digestive tract.[1]

Distribution

Once absorbed into the systemic circulation, piroxicam is extensively bound to plasma proteins, primarily albumin. The degree of protein binding is approximately 99%.[6] This high level of binding restricts the drug's distribution in the body, resulting in a small apparent volume of distribution (

Vd​) of about 0.14 L/kg.[3] Despite being highly protein-bound, piroxicam effectively penetrates into the synovial fluid of joints, a critical feature for its efficacy in treating arthritis. Concentrations in the synovial fluid reach approximately 40% to 50% of those in the plasma.[6] Piroxicam is also known to be excreted into human breast milk, appearing at concentrations that are about 1% to 3% of the maternal plasma concentration.[7]

Metabolism

Piroxicam undergoes extensive biotransformation in the liver, with less than 5% of a dose being excreted as the unchanged parent drug.[3] The primary metabolic pathway is hydroxylation at the 5-position of the pyridyl side chain, which forms its major metabolite, 5'-hydroxypiroxicam.[7] This metabolite is pharmacologically inactive, meaning the drug's therapeutic effects are attributable solely to the parent compound.[21]

This critical hydroxylation step is catalyzed almost exclusively by a single enzyme from the cytochrome P450 superfamily: CYP2C9.[8] This near-total reliance on a single metabolic pathway has significant clinical implications. The gene encoding CYP2C9 is highly polymorphic, meaning there are common genetic variations in the population that result in enzymes with reduced or absent function. Individuals who are "intermediate metabolizers" or "poor metabolizers" of CYP2C9 substrates clear piroxicam much more slowly than those with normal enzyme function ("normal metabolizers").[8] This reduced metabolic clearance leads to abnormally high plasma concentrations of piroxicam and a prolonged half-life, substantially increasing the risk of adverse drug reactions. Published reports have shown that subjects with certain variant genotypes can have systemic piroxicam levels up to 5.3-fold higher than normal metabolizers.[9] Consequently, the FDA-approved labeling recommends considering a dose reduction in patients known or suspected to be CYP2C9 poor metabolizers.[8]

Excretion

The parent drug and its biotransformation products are eliminated from the body through both renal and fecal routes. Approximately twice as much of the dose is excreted in the urine compared to the feces.[3]

Half-Life and Dosing Implications

Piroxicam is characterized by an exceptionally long elimination half-life (t1/2​), which averages around 50 hours but exhibits considerable interindividual variability, with a reported range of 30 to 86 hours.[3] This prolonged half-life is the primary reason that stable, steady-state plasma concentrations are not achieved for 7 to 12 days after initiating therapy.[7] While therapeutic effects may be evident early, the full response may not be assessable for up to two weeks. The key clinical advantage of this long half-life is that it allows for effective, once-daily dosing, which can improve patient adherence.[3]

However, the combination of its pharmacokinetic properties—a long half-life leading to drug accumulation, non-selective COX inhibition, and reliance on a single polymorphic metabolic enzyme—creates a synergistic potential for toxicity. This convergence of factors provides a strong mechanistic basis for the observation that piroxicam carries a higher risk of serious gastrointestinal and cutaneous adverse events compared to many shorter-acting NSAIDs, a finding that has prompted significant regulatory action and a re-evaluation of its place in therapy.

Table 2: Summary of Piroxicam Pharmacokinetic Parameters

Parameter	Value	Comment/Significance	Source(s)
Time to Peak (Tmax)	3–5 hours	Time to reach maximum plasma concentration after oral dose.	7
Bioavailability	Well absorbed	Extent of absorption is high; rate can be slowed by food.	6
Plasma Protein Binding	~99%	Highly bound, primarily to albumin, resulting in a low volume of distribution.	6
Volume of Distribution (Vd​)	~0.14 L/kg	Small volume of distribution, typical for highly protein-bound drugs.	3
Primary Metabolic Enzyme	CYP2C9	Near-exclusive reliance on this polymorphic enzyme is a key factor in toxicity risk.	8
Major Metabolite	5'-hydroxypiroxicam	Pharmacologically inactive.	8
Elimination Half-life (t1/2​)	~50 hours (range 30–86)	Exceptionally long; allows for once-daily dosing but leads to accumulation.	6
Time to Steady State	7–12 days	Full therapeutic effect may not be seen for up to two weeks.	7
Route of Elimination	Urine (~66%) and Feces (~33%)	Excreted primarily as metabolites.	3

Clinical Applications, Dosage, and Administration

The clinical use of piroxicam has evolved significantly since its introduction, shaped by an increasing understanding of its risk-benefit profile. Once a widely used anti-inflammatory agent for a broad range of conditions, its indications have been narrowed in many regions due to safety concerns.

Approved and Restricted Indications

In the United States, piroxicam is approved by the FDA for the symptomatic relief of osteoarthritis and rheumatoid arthritis.[4] It is effective in reducing pain, stiffness, swelling, and inflammation associated with these chronic degenerative and inflammatory joint diseases.[3]

The regulatory landscape in Europe is substantially more restrictive. Following a comprehensive review in 2007, the European Medicines Agency (EMA) concluded that piroxicam's risk-benefit ratio was only favorable for chronic inflammatory conditions.[1] This was based on epidemiological evidence suggesting a significantly greater risk of serious gastrointestinal and skin reactions compared to other NSAIDs.[11] As a result, the EMA recommended that:

• Systemic piroxicam should no longer be used for any acute painful or inflammatory conditions, such as primary dysmenorrhea, postoperative pain, or acute musculoskeletal disorders.[11]
• It should only be used as a second-line treatment for the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients for whom other NSAIDs are not suitable.[11]
• Initiation of therapy should be done only by physicians with experience in treating these chronic rheumatic diseases.[11]

This shift from a first-line, broad-spectrum agent to a restricted, second-line therapy reflects a critical re-evaluation of its place in medicine, prioritizing patient safety over its established efficacy and convenient dosing.

Historical and Off-Label Uses

Historically and in some regions, piroxicam has been used for a wider array of conditions. These include ankylosing spondylitis (arthritis primarily affecting the spine), acute gouty arthritis, primary dysmenorrhea (menstrual pain), and acute musculoskeletal disorders.[1] It has also been applied in the treatment of

frozen shoulder and temporomandibular joint disorder.[15] Clinical trials have also investigated its utility in specific pain scenarios, such as toothache following dental procedures.[32] While effective in these settings, its use for acute conditions is now discouraged in many jurisdictions due to the unfavorable risk profile for short-term therapy.

Dosage Forms and Strengths

Piroxicam is primarily available for systemic use as oral capsules. The standard strengths available are 10 mg and 20 mg.[4] In some countries, a topical formulation, such as a 0.5% gel, is available for localized application, which is not subject to the same systemic use restrictions.[1]

Recommended Dosing Regimens

The guiding principle for all NSAID therapy, including piroxicam, is to use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.[7]

• Adults: For both osteoarthritis and rheumatoid arthritis, the recommended dosage is 20 mg administered orally once daily. If desired, this daily dose may be divided into 10 mg taken twice daily.[4] Due to safety concerns, the maximum daily dose should not exceed 20 mg.[11]
• Children: For Juvenile Rheumatoid Arthritis, dosing is based on body weight. For example, a child weighing 16 to 25 kg would receive 10 mg daily, while one weighing 26 to 45 kg would receive 15 mg daily.[16] Safety and efficacy have not been established in children for other indications.[34]
• Special Populations: Dose reduction should be considered for patients with liver disease and those who are known or suspected to be CYP2C9 poor metabolizers.[8] In elderly patients, if the benefits are deemed to outweigh the risks, therapy should be initiated at the low end of the dosing range.[31]

Administration

Piroxicam capsules are taken orally. They can be administered with or without food. However, to minimize the potential for gastrointestinal irritation and upset, it is often recommended to take the medication with food, milk, or a full glass of water.[36]

Safety Profile: Adverse Effects and Black Box Warnings

The clinical use of piroxicam is heavily influenced by its safety profile, which is characterized by risks common to all NSAIDs but amplified in severity and frequency for certain adverse events. These concerns have led to the most stringent warnings from regulatory agencies and have reshaped its therapeutic role.

U.S. FDA Black Box Warnings

Piroxicam's labeling in the United States includes two prominent Black Box Warnings, which are reserved for drugs with the potential for serious or life-threatening risks.[7]

Cardiovascular Thrombotic Events

All NSAIDs, including piroxicam, are associated with an increased risk of serious and potentially fatal cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke.[7]

• Risk Population: The risk may be higher in patients with pre-existing cardiovascular disease or risk factors (e.g., hypertension, hyperlipidemia), but it is also elevated in patients without known disease.[43]
• Onset and Duration: This risk can emerge as early as the first weeks of treatment and may increase with longer duration of use and higher doses.[43]
• Clinical Context: Piroxicam is explicitly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, as clinical trials in this setting found an increased incidence of MI and stroke.[7]

Gastrointestinal Bleeding, Ulceration, and Perforation

Piroxicam carries a significant risk of causing serious and potentially fatal gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines.[7]

• Risk Population: Elderly patients are at a particularly high risk for these complications. A prior history of peptic ulcer disease or GI bleeding increases the risk more than tenfold.[7]
• Onset and Warning Signs: These events can occur at any time during treatment and often without preceding warning symptoms.[10]
• Relative Risk: Epidemiological studies suggest that piroxicam is associated with a higher risk of serious GI toxicity compared to many other non-selective NSAIDs, a key factor in the regulatory restrictions imposed by agencies like the EMA.[11]

Common Adverse Effects

The most frequently reported side effects are generally mild to moderate and often related to the gastrointestinal system. These include:

• Gastrointestinal: Dyspepsia (heartburn), nausea, abdominal pain or discomfort, diarrhea, constipation, and flatulence.[1]
• Central Nervous System: Dizziness, headache, and somnolence (drowsiness).[1]
• Otic: Tinnitus (ringing in the ears).[1]
• General: Peripheral edema (swelling of the feet or ankles).[4]

Serious Adverse Events (Beyond Black Box)

Beyond the black-boxed risks, piroxicam is associated with several other serious, albeit less common, adverse events.

• Hepatotoxicity: Piroxicam can cause liver injury. While mild, asymptomatic elevations in serum aminotransferase levels are reported in 3% to 18% of patients, clinically apparent acute liver injury is rare (estimated at 1 to 5 cases per 100,000 prescriptions). When it occurs, the injury is often cholestatic in nature and can be severe and, in rare instances, fatal. Onset is typically within the first 1 to 6 weeks of treatment.[4]
• Renal Toxicity and Hyperkalemia: Like all NSAIDs, piroxicam can impair renal function by inhibiting the synthesis of renal prostaglandins, which are vital for maintaining renal blood flow. This can lead to renal papillary necrosis, acute renal failure, and fluid retention. The risk is highest in patients who are elderly or have pre-existing kidney disease, heart failure, liver dysfunction, or are volume-depleted.[4] It can also cause hyperkalemia (elevated potassium levels).[5]
• Serious Skin Reactions: Piroxicam is associated with a risk of rare but life-threatening cutaneous reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). These conditions involve severe blistering and peeling of the skin and mucous membranes and require immediate medical intervention. Evidence from observational studies suggests that piroxicam may carry a higher risk of these reactions than other non-oxicam NSAIDs, with most cases occurring within the first month of therapy.[11]
• Anaphylactic and Hypersensitivity Reactions: Severe, life-threatening allergic reactions (anaphylaxis) can occur, particularly in patients with a known sensitivity to aspirin or other NSAIDs.[5]
• Hematologic Toxicity: Piroxicam can cause anemia, which may be due to occult GI blood loss. It also inhibits platelet aggregation and can prolong bleeding time.[5]
• Fetal Toxicity: Use of NSAIDs, including piroxicam, during the third trimester of pregnancy (after 30 weeks gestation) is not recommended due to the risk of premature closure of the fetal ductus arteriosus. Use between 20 and 30 weeks may cause rare but serious fetal renal dysfunction leading to oligohydramnios (low amniotic fluid).[4]

The overall safety profile, particularly the elevated relative risk of severe GI and skin reactions, is the primary factor that has led to the re-evaluation and restriction of piroxicam's use in modern clinical practice. It serves as a prominent example of how post-marketing pharmacovigilance can fundamentally alter the therapeutic landscape of a drug.

Contraindications, Warnings, and Precautions

The significant risks associated with piroxicam therapy necessitate a clear understanding of situations where its use is either absolutely contraindicated or requires extreme caution. These guidelines are designed to protect patients most vulnerable to its adverse effects.

Absolute Contraindications

Piroxicam should not be administered to patients under the following circumstances:

• Known Hypersensitivity: Patients with a known hypersensitivity or history of anaphylactic reactions or serious skin reactions to piroxicam or any of its excipients are contraindicated.[8]
• Aspirin or NSAID-Induced Hypersensitivity: Patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs should not receive piroxicam. This condition, often termed aspirin-exacerbated respiratory disease, carries a risk of severe, potentially fatal bronchospasm and anaphylactic reactions upon exposure to any COX inhibitor.[8]
• Coronary Artery Bypass Graft (CABG) Surgery: Piroxicam is strictly contraindicated for the treatment of peri-operative pain immediately before or after CABG surgery. Clinical trials have demonstrated an increased risk of myocardial infarction and stroke in this setting.[7]
• Active Peptic Ulcer or GI Bleeding: Some regulatory bodies, such as in Canada, list active gastrointestinal bleeding or ulceration as an absolute contraindication.[39]

Warnings and Precautions for High-Risk Populations

Beyond absolute contraindications, there are numerous patient populations and clinical scenarios where piroxicam must be used with significant caution, if at all.

• Elderly Patients: This group is at a substantially increased risk for nearly all serious NSAID-related adverse events, particularly gastrointestinal bleeding, cardiovascular events, and renal toxicity. The American Geriatrics Society's Beers Criteria identify piroxicam as a potentially inappropriate medication for chronic use in adults aged 65 and older due to its high risk of GI bleeding and its long half-life, which leads to accumulation.[39] Use should be avoided entirely in patients over 80 years of age.[11]
• Patients with Cardiovascular Disease: Use with extreme caution in patients with known cardiovascular disease (e.g., ischemic heart disease, cerebrovascular disease), risk factors for CV disease, a recent myocardial infarction, congestive heart failure, or hypertension. NSAIDs can worsen these conditions and increase the risk of further thrombotic events.[5]
• Patients with Gastrointestinal Disease History: Patients with a prior history of peptic ulcers or GI bleeding are at a dramatically elevated risk of recurrence when taking NSAIDs. Piroxicam should be prescribed with extreme caution in this population, and alternative therapies should be strongly considered.[7]
• Patients with Renal or Hepatic Impairment: Since piroxicam is metabolized by the liver and its metabolites are cleared by the kidneys, it should be used with caution in patients with hepatic or renal dysfunction. Dose adjustments may be necessary for liver disease, and the drug should generally be avoided in patients with advanced renal disease.[16]
• Pregnancy and Lactation: Piroxicam should be avoided in pregnant women starting from 20 weeks of gestation due to the risk of fetal renal dysfunction and oligohydramnios. Its use is contraindicated in the third trimester (from 30 weeks) due to the risk of premature closure of the fetal ductus arteriosus.[4] As the drug is excreted in breast milk, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.[5]
• Fertility: Piroxicam, like other NSAIDs, may cause a reversible delay in ovulation and has been associated with temporary infertility in some women.[4]

These extensive warnings and contraindications effectively delineate the patient populations for whom piroxicam is not a suitable therapeutic choice. They are not arbitrary but are direct, evidence-based responses to the drug's known mechanistic liabilities, such as COX-1 inhibition and effects on renal prostaglandins. The breadth of these precautions underscores why many clinical guidelines now favor agents with a perceived better safety profile as first-line options for pain and inflammation.

Clinically Significant Interactions

The use of piroxicam is complicated by a large number of potential interactions with other drugs, as well as with alcohol and tobacco. These interactions can significantly increase the risk of adverse events or reduce the efficacy of concurrent therapies. There are over 400 documented drug interactions with piroxicam, with more than 100 classified as major.[49] The interaction profile is largely defined by two major themes: a synergistic increase in bleeding risk and an antagonistic effect on cardiovascular and renal therapies, making its use particularly challenging in older adults with common comorbidities who are often on multiple medications.

Drug-Drug Interactions

Interactions can be broadly categorized as pharmacodynamic (where drugs have additive or opposing effects) or pharmacokinetic (where one drug affects the absorption, distribution, metabolism, or excretion of another).

• Pharmacodynamic Interactions:
• Anticoagulants and Antiplatelet Agents: The most critical interaction is with drugs that affect hemostasis. Concomitant use of piroxicam with anticoagulants (e.g., warfarin), antiplatelet drugs (e.g., aspirin, clopidogrel), or selective serotonin reuptake inhibitors (SSRIs) dramatically increases the risk of serious bleeding, especially gastrointestinal bleeding. Piroxicam inhibits platelet function via COX-1 inhibition, and this effect is additive with other antithrombotic agents.[10]
• Other NSAIDs and Corticosteroids: Combining piroxicam with other NSAIDs (including over-the-counter agents like ibuprofen and naproxen) or with oral corticosteroids (e.g., prednisone) provides no additional therapeutic benefit and substantially increases the risk of GI ulceration and bleeding.[10]
• Antihypertensive Medications: Piroxicam can reduce or antagonize the blood pressure-lowering effects of several classes of antihypertensive drugs, including ACE inhibitors (e.g., lisinopril), angiotensin II receptor blockers (ARBs), beta-blockers, and diuretics ("water pills"). This occurs because NSAIDs inhibit the synthesis of vasodilating renal prostaglandins. This interaction can lead to a loss of blood pressure control and may also increase the risk of acute renal impairment, especially in elderly or volume-depleted patients.[34]
• Pharmacokinetic Interactions:
• Lithium, Methotrexate, and Digoxin: Piroxicam can reduce the renal clearance of these drugs, which have narrow therapeutic indices. This can lead to an accumulation of lithium, methotrexate, or digoxin in the body, resulting in potentially severe toxicity.[30]
• CYP2C9 Substrates, Inhibitors, and Inducers: As piroxicam is a substrate of the CYP2C9 enzyme, its plasma concentrations can be affected by other drugs that interact with this enzyme. Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) can increase piroxicam levels and the risk of toxicity. Conversely, CYP2C9 inducers (e.g., rifampin) can decrease piroxicam levels, potentially reducing its efficacy.[25]

Lifestyle Interactions

• Alcohol: The concurrent consumption of alcohol with piroxicam is a major interaction that should be avoided. Alcohol is a direct irritant to the gastric mucosa and, when combined with the COX-1 inhibiting effects of piroxicam, significantly increases the risk of stomach irritation, ulceration, and life-threatening GI bleeding.[34]
• Tobacco: Smoking is an independent risk factor for peptic ulcer disease. When combined with NSAID use, it further enhances the risk of serious GI side effects.[51]

Table 3: Major Drug-Drug Interactions with Piroxicam

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Recommendation	Source(s)
Anticoagulants (e.g., Warfarin)	Pharmacodynamic: Additive antiplatelet/anticoagulant effects.	Markedly increased risk of serious bleeding, especially GI hemorrhage.	Avoid combination; if necessary, monitor closely for signs of bleeding.	10
Antiplatelet Agents (e.g., Aspirin)	Pharmacodynamic: Additive inhibition of platelet aggregation.	Increased risk of GI bleeding and ulceration.	Avoid concurrent use of analgesic doses of aspirin. Use with low-dose aspirin increases GI risk.	10
Other NSAIDs (e.g., Ibuprofen)	Pharmacodynamic: Additive COX inhibition.	Substantially increased risk of GI toxicity with no efficacy benefit.	Combination is contraindicated.	34
Corticosteroids (e.g., Prednisone)	Pharmacodynamic: Additive risk of gastric mucosal injury.	Increased risk of GI ulceration and bleeding.	Use with caution; consider gastroprotective therapy.	10
ACE Inhibitors / ARBs	Pharmacodynamic: Inhibition of renal prostaglandins.	Blunted antihypertensive effect; increased risk of renal impairment.	Monitor blood pressure and renal function closely.	37
Diuretics (Loop, Thiazide)	Pharmacodynamic: Inhibition of renal prostaglandins.	Reduced diuretic and natriuretic effect; increased risk of nephrotoxicity.	Monitor for fluid retention, blood pressure, and renal function.	34
Lithium	Pharmacokinetic: Decreased renal clearance of lithium.	Increased plasma lithium levels and risk of toxicity.	Avoid combination or monitor lithium levels frequently.	30
Methotrexate	Pharmacokinetic: Decreased renal clearance of methotrexate.	Elevated methotrexate levels, leading to severe hematologic and GI toxicity.	Avoid combination, especially with high-dose methotrexate.	30
CYP2C9 Inhibitors (e.g., Fluconazole)	Pharmacokinetic: Inhibition of piroxicam metabolism.	Increased piroxicam plasma levels and risk of adverse effects.	Use with caution; consider dose reduction of piroxicam.	25

Comparative Analysis within the NSAID Class

Piroxicam's position in the therapeutic armamentarium is best understood through a comparative lens, evaluating its efficacy and safety relative to other commonly prescribed NSAIDs. This analysis reveals that while its efficacy is generally comparable to its peers, its safety profile is often less favorable, which has driven its reclassification as a second-line agent in many clinical guidelines.

Efficacy Comparison

Numerous clinical trials have compared piroxicam to other NSAIDs across various inflammatory conditions.

• vs. Naproxen: For osteoarthritis of the knee, studies have found that piroxicam (20 mg/day) is as effective as naproxen in relieving pain and improving joint function, with some evidence suggesting it may have fewer adverse effects like epigastric discomfort.[53] In acute musculoskeletal disorders, both drugs proved similarly effective.[54] However, another study in athletes with acute injuries found that piroxicam provided statistically superior reduction in spontaneous pain, swelling, and tenderness after three days of treatment compared to naproxen.[55] A meta-analysis of randomized controlled trials (RCTs) found piroxicam to be significantly superior to naproxen for global efficacy outcomes.[56]
• vs. Diclofenac: Studies comparing piroxicam to diclofenac have shown similar efficacy in treating conditions like primary dysmenorrhea.[58] For topical formulations, both piroxicam gel and diclofenac gel are effective for localized pain, with a network meta-analysis suggesting diclofenac patches may be most effective for pain relief in osteoarthritis, while piroxicam gel may be most effective for functional improvement.[60]
• vs. Ibuprofen: A double-blinded trial in patients with chronic non-rheumatic joint pain found that, as a group, patients experienced better pain relief on piroxicam compared to ibuprofen.[62] User ratings on Drugs.com show a slightly higher average score for piroxicam (7.9/10) compared to ibuprofen (7.3/10).[63]
• vs. Ketoprofen: In a study of patients with rheumatoid arthritis, once-daily extended-release ketoprofen and piroxicam produced comparable therapeutic improvements.[64] For topical use in rheumatoid arthritis, one study concluded that ketoprofen cream provided better pain relief and functional improvement than both diclofenac and piroxicam creams.[65]
• vs. Meloxicam: Meloxicam is another oxicam NSAID. A 6-week study in patients with osteoarthritis of the hip found that meloxicam (15 mg/day) was comparable in efficacy and safety to piroxicam (20 mg/day).[66]
• vs. Celecoxib (COX-2 Selective): In osteoarthritis, NSAIDs as a class (including piroxicam) and celecoxib offer similar degrees of pain relief.[53] User ratings on Drugs.com are higher for piroxicam (7.9/10) than for celecoxib (7.0/10).[67]

Overall, the evidence suggests that piroxicam is an effective anti-inflammatory and analgesic agent, with an efficacy profile that is largely comparable to, and in some specific instances potentially superior to, other widely used non-selective NSAIDs.

Safety Profile Comparison

The critical differentiator for piroxicam is its safety profile. While efficacy is comparable, its risk of certain serious adverse events is considered to be higher than many alternatives.

• Gastrointestinal (GI) Toxicity: This is the area of greatest concern. Large-scale epidemiological data, which informed the EMA's decision to restrict its use, consistently indicate that piroxicam carries a significantly higher risk of serious GI complications (ulceration, bleeding, perforation) than other non-selective NSAIDs like ibuprofen and naproxen.[11] One large study directly comparing a combination of diclofenac/misoprostol to piroxicam and naproxen found that the incidence of gastroduodenal ulcers was 1.5% in the diclofenac/misoprostol group versus 10.3% in the piroxicam group.[69] This elevated risk is a direct consequence of its potent, non-selective COX inhibition combined with its very long half-life, which leads to prolonged exposure of the gastric mucosa to the drug's effects.[44] In contrast to this real-world data, some meta-analyses of shorter-term RCTs have paradoxically suggested piroxicam has a better GI safety profile than naproxen and indomethacin, though worse than the more COX-2 selective oxicam, meloxicam.[56] This discrepancy highlights the limitations of RCTs, which often exclude high-risk patients and are of shorter duration, in capturing the full spectrum of risk seen in broad clinical practice.
• Cardiovascular (CV) Toxicity: All non-selective NSAIDs and COX-2 inhibitors carry an increased risk of cardiovascular thrombotic events. There is no clear evidence that piroxicam's CV risk is substantially different from other non-selective agents like naproxen or ibuprofen, but it is considered higher than that of a non-NSAID analgesic.[41]
• Cutaneous (Skin) Reactions: Observational studies suggest that piroxicam may be associated with a higher risk of severe skin reactions (SJS/TEN) than other non-oxicam NSAIDs.[11]

In summary, piroxicam's clinical profile is defined by a distinct trade-off. It offers the convenience of once-daily dosing due to its long half-life, with an efficacy that is on par with its competitors. However, this same pharmacokinetic property, combined with its potent inhibition of COX-1, results in a safety profile—particularly regarding severe GI and skin reactions—that is demonstrably less favorable than many other available NSAIDs. The absence of a clear efficacy advantage to justify this increased risk for the majority of patients is the fundamental rationale behind its diminished role in clinical practice and its restriction by major regulatory agencies.

Global Regulatory Landscape and Commercialization

The journey of piroxicam from a widely prescribed, first-line anti-inflammatory to a more restricted, second-line agent is a compelling case study in pharmacovigilance and evolving global regulatory standards. Its commercial status has been shaped by its efficacy, safety profile, patent lifecycle, and divergent assessments by major health authorities.

Regulatory History and Commercialization

Piroxicam was developed by Pfizer, with the initial research project beginning in 1962. Following successful clinical trials, it was launched in 1980 under the well-known brand name Feldene.[1] Its long half-life and consequent once-daily dosing regimen were significant advantages over older NSAIDs, contributing to its initial commercial success. The major patents for piroxicam expired in 1992, which opened the market to a proliferation of generic versions.[1] This genericization has made piroxicam a low-cost and widely available option, particularly in developing countries, but has also led to significant price erosion and increased competition, diminishing revenues from the original branded product.[71]

U.S. Food and Drug Administration (FDA) Status

In the United States, piroxicam is a prescription-only (℞-only) medication.[1] It is approved for the symptomatic relief of osteoarthritis and rheumatoid arthritis.[8] The FDA's regulatory approach has focused on risk communication through stringent labeling requirements. The U.S. label for piroxicam prominently features

Black Box Warnings for both cardiovascular and gastrointestinal risks, informing prescribers and patients of the potential for severe, life-threatening events.[38] In October 2020, the FDA mandated that the labels for all NSAIDs, including piroxicam, be updated to include the risk of fetal kidney problems leading to low amniotic fluid.[1] The FDA labeling also incorporates pharmacogenomic information, specifically recommending that a dose reduction be considered for patients who are known or suspected to be poor metabolizers via the CYP2C9 enzyme pathway.[9] Numerous generic manufacturers have received approval for piroxicam capsules through the Abbreviated New Drug Application (ANDA) process.[72]

European Medicines Agency (EMA) Status

The EMA and national agencies within the European Union have adopted a more restrictive regulatory stance. In 2007, following a comprehensive safety review, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended significant limitations on the use of systemic piroxicam.[1] This review was prompted by consistent epidemiological evidence showing that piroxicam was associated with a higher risk of serious gastrointestinal side effects and severe skin reactions compared to other non-selective NSAIDs.[11]

The EMA's recommendations, which became legally binding across the EU, included:

• Restricting its indications to the symptomatic, second-line treatment of chronic conditions: osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.[11]
• Removing its approval for all acute pain and inflammatory conditions.[11]
• Recommending that the first prescription be initiated only by a specialist and that treatment be reviewed after 14 days.[11]
• Establishing a maximum daily dose of 20 mg.[11]

This regulatory action in Europe was shown to be both clinically beneficial and cost-effective. A retrospective economic evaluation in Spain concluded that the restriction of piroxicam use avoided cases of serious GI complications and resulted in significant overall cost savings for the healthcare system.[73] The EMA continues to monitor the drug's safety through Periodic Safety Update Reports (PSURs).[74]

The divergent regulatory paths taken by the FDA and the EMA highlight different approaches to managing drug risk. The FDA's strategy relies heavily on informing prescribers of the risks via labeling, placing the final risk-benefit decision on the individual clinician. In contrast, the EMA's approach represents a more direct, population-level risk management strategy by structurally limiting the drug's approved uses and access.

Other Regulatory Jurisdictions

Consistent with the US and EU, piroxicam is a prescription-only medicine in other major jurisdictions, including Australia (Schedule 4), Canada (℞-only), and the United Kingdom (Prescription Only Medicine - POM).[1]

International Brand Names

While Feldene is the original and most widely recognized brand name, the expiration of its patent has led to its marketing worldwide under a vast number of different trade names. A representative list of these global brand names includes:

• Abxicam (Pakistan) [75]
• Apo-Piroxicam (Canada, Singapore) [75]
• Artrilase (Ecuador) [75]
• Baxo (Japan) [75]
• Brexin (Latvia, Lithuania) [75]
• Dolonex (India) [75]
• Erazon (Croatia) [75]
• Facicam (Mexico) [75]
• Felcam (Indonesia, Taiwan) [75]
• Novo-Pirocam (United States) [4]

Many formulations are also available as combination products, particularly in Latin America, where piroxicam is combined with agents like paracetamol, muscle relaxants (orphenadrine, carisoprodol), or vitamins.[75]

Conclusion and Expert Recommendations

Piroxicam is a potent non-steroidal anti-inflammatory drug with established efficacy in managing chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis. Its clinical profile is uniquely defined by a significant trade-off: its exceptionally long elimination half-life provides the convenience of a once-daily dosing regimen but is also the primary driver of a heightened risk profile. This prolonged duration of action, combined with its non-selective inhibition of both COX-1 and COX-2 enzymes and its reliance on the polymorphic CYP2C9 enzyme for metabolism, creates a synergistic potential for severe adverse events.

The cumulative evidence from decades of clinical use and large-scale epidemiological studies has demonstrated that piroxicam carries a comparatively higher risk of serious gastrointestinal toxicity and severe cutaneous reactions than many other available NSAIDs. While its efficacy is generally not superior to these alternatives, its risk is demonstrably greater. This unfavorable risk-benefit balance is the fundamental reason for the evolution of its place in therapy, from a first-line agent to a more restricted, second-line option in many parts of the world.

Based on a comprehensive analysis of its pharmacology, clinical data, and regulatory history, the following expert recommendations are provided for the clinical use of piroxicam:

Place in Therapy

• Second-Line Agent: Piroxicam should be considered a second-line agent for the symptomatic treatment of osteoarthritis and rheumatoid arthritis, consistent with guidelines from the European Medicines Agency. Its use should be reserved for patients who have had an inadequate response to, or are intolerant of, other NSAIDs with a more favorable safety profile (e.g., naproxen, ibuprofen).
• Avoid in Acute Pain: The use of systemic piroxicam for acute pain conditions (e.g., musculoskeletal injuries, dysmenorrhea, postoperative pain) is not recommended due to an unfavorable risk-benefit profile for short-term therapy.

Patient Selection and Risk Mitigation

• Thorough Risk Assessment: Before initiating therapy, a comprehensive assessment of the patient's individual cardiovascular and gastrointestinal risk factors is mandatory. Piroxicam should be avoided in high-risk patients, including the elderly (especially those >80 years), individuals with a history of peptic ulcer disease or GI bleeding, those with active cardiovascular disease, and patients receiving concurrent anticoagulant or antiplatelet therapy.
• Gastroprotection: Co-prescription of a gastroprotective agent, such as a proton pump inhibitor (PPI), should be strongly considered for all patients receiving piroxicam, particularly those with any identifiable risk factors for GI toxicity.
• Pharmacogenomic Consideration: In patients with a history of sensitivity to other CYP2C9 substrates (e.g., warfarin, phenytoin) or where genotyping is available, the possibility of a CYP2C9 poor metabolizer status should be considered. In such cases, an alternative agent not metabolized by CYP2C9 is preferable, or a significant dose reduction of piroxicam is required.

Dosing and Monitoring

• Lowest Effective Dose: Adherence to the principle of using the lowest effective dose for the shortest possible duration is critical. The daily dose should not exceed 20 mg.
• Regular Monitoring: Patients on long-term piroxicam therapy require regular monitoring. This should include periodic assessment of blood pressure, renal function (serum creatinine), and for signs of occult GI bleeding (complete blood count to check for anemia).
• Treatment Review: The continued need for therapy should be reviewed regularly, for instance, within the first few weeks of initiation and frequently thereafter.

Patient Counseling

• Informed Consent: Patients must be thoroughly counseled on the potential risks and benefits of piroxicam therapy.
• Warning Signs: Patients should be educated to recognize and immediately report the warning signs of serious adverse events, including:
• Cardiovascular: Chest pain, shortness of breath, weakness on one side of the body, or slurred speech.
• Gastrointestinal: Black or tarry stools, vomiting blood or material that looks like coffee grounds, or severe stomach pain.
• Cutaneous: Any new rash, blistering, or peeling of the skin.
• Lifestyle Interactions: Patients should be strongly advised to avoid consuming alcohol while taking piroxicam and to avoid the concurrent use of any other over-the-counter NSAIDs unless specifically approved by their healthcare provider.

In conclusion, while piroxicam remains an effective therapeutic option for a select group of patients, its use in modern clinical practice demands a cautious and highly individualized approach that prioritizes safety and risk mitigation.

Works cited

1. Piroxicam - Wikipedia, accessed September 12, 2025, https://en.wikipedia.org/wiki/Piroxicam
2. Definition of piroxicam - NCI Drug Dictionary, accessed September 12, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/piroxicam
3. Piroxicam: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 12, 2025, https://go.drugbank.com/drugs/DB00554
4. Piroxicam - LiverTox - NCBI Bookshelf, accessed September 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548425/
5. Piroxicam (oral route) - Side effects & dosage - Mayo Clinic, accessed September 12, 2025, https://www.mayoclinic.org/drugs-supplements/piroxicam-oral-route/description/drg-20069771
6. Clinical pharmacokinetics of piroxicam - PubMed, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/3490574/
7. FELDENE® (piroxicam) CAPSULES 10 mg and 20 mg For Oral Use, accessed September 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018147s029lbl.pdf
8. Piroxicam Therapy and CYP2C9 Genotype - Medical Genetics Summaries - NCBI Bookshelf, accessed September 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK537367/
9. Annotation of FDA Label for piroxicam and CYP2C9 - ClinPGx, accessed September 12, 2025, https://www.clinpgx.org/labelAnnotation/PA166105222
10. Piroxicam: MedlinePlus Drug Information, accessed September 12, 2025, https://medlineplus.gov/druginfo/meds/a684045.html
11. Piroxicam: new restrictions, including specialist initiation - GOV.UK, accessed September 12, 2025, https://www.gov.uk/drug-safety-update/piroxicam-new-restrictions-including-specialist-initiation
12. European Medicines Agency recommends restricted use for piroxicam - ResearchGate, accessed September 12, 2025, https://www.researchgate.net/publication/270679599_A_Randomized_Open_Label_2-Way_Crossover_Study_to_Assess_the_Pharmacokinetic_Characteristics_and_Skin_Irritation_of_MurupeR_Patch_Compared_with_TrastR_Patch_in_Healthy_Volunteers/fulltext/55d65a2a08aec156b9a85739/A-Randomized-Open-Label-2-Way-Crossover-Study-to-Assess-the-Pharmacokinetic-Characteristics-and-Skin-Irritation-of-MurupeR-Patch-Compared-with-TrastR-Patch-in-Healthy-Volunteers.pdf
13. Piroxicam | C15H13N3O4S | CID 54676228 - PubChem, accessed September 12, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Piroxicam
14. CAS 36322-90-4 Piroxicam - BOC Sciences, accessed September 12, 2025, https://www.bocsci.com/product/piroxicam-cas-36322-90-4-91073.html
15. Piroxicam - brand name list from Drugs.com, accessed September 12, 2025, https://www.drugs.com/ingredient/piroxicam.html
16. PIROXICAM - Pfizer, accessed September 12, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12878
17. www.caymanchem.com, accessed September 12, 2025, [https://www.caymanchem.com/product/13368/piroxicam#:~:text=Product%20Description,anti%2Dinflammatory%20and%20analgesic%20properties.&text=It%20inhibits%20production%20of%20thromboxane,from%20arachidonic%20acid%20(Item%20Nos.](https://www.google.com/url?q=https://www.caymanchem.com/product/13368/piroxicam%23:~:text%3DProduct%2520Description,anti%252Dinflammatory%2520and%2520analgesic%2520properties.%26text%3DIt%2520inhibits%2520production%2520of%2520thromboxane,from%2520arachidonic%2520acid%2520(Item%2520Nos.&sa=D&source=editors&ust=1757672859696465&usg=AOvVaw3Qf8x7hAerAj-_5d1L2Nyk)
18. What is the mechanism of Piroxicam? - Patsnap Synapse, accessed September 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-piroxicam
19. Piroxicam | CAS 36322-90-4 - Tocris Bioscience, accessed September 12, 2025, https://www.tocris.com/products/piroxicam_0960
20. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents - PubMed, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/8162655/
21. Piroxicam - IARC Publications, accessed September 12, 2025, https://publications.iarc.who.int/_publications/media/download/3838/0fb3320052b5eff7400a6e0a4205e959f59e8b38.pdf
22. Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs - ResearchGate, accessed September 12, 2025, https://www.researchgate.net/publication/16844429_Clinical_Pharmacokinetics_of_Non-steroidal_Anti-inflammatory_Drugs
23. piroxicam - ClinPGx, accessed September 12, 2025, https://www.clinpgx.org/chemical/PA450985
24. Piroxicam Pathway, Pharmacokinetics - ClinPGx, accessed September 12, 2025, https://www.clinpgx.org/pathway/PA166246241
25. Showing BioInteractions for Piroxicam (DB00554) | DrugBank Online, accessed September 12, 2025, https://go.drugbank.com/drugs/DB00554/biointeractions
26. feldene - accessdata.fda.gov, accessed September 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018147_S052LBL.pdf
27. Non-Selective NSAIDS - Cardiovascular, Skin and Gastrointestinal Risks - Medsafe, accessed September 12, 2025, https://www.medsafe.govt.nz/profs/PUArticles/NSAIDSRisks.htm
28. Piroxicam: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed September 12, 2025, https://www.medcentral.com/drugs/monograph/10942-384045/piroxicam-oral
29. Piroxicam | Davis's Drug Guide for Rehabilitation Professionals, accessed September 12, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139022640
30. Piroxicam Uses, Side Effects & Warnings - Drugs.com, accessed September 12, 2025, https://www.drugs.com/mtm/piroxicam.html
31. Piroxicam Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 12, 2025, https://www.drugs.com/dosage/piroxicam.html
32. Toothache Completed Phase 3 Trials for Piroxicam (DB00554) | DrugBank Online, accessed September 12, 2025, https://go.drugbank.com/indications/DBCOND0001908/clinical_trials/DB00554?phase=3&status=completed
33. Piroxicam Completed Phase 1 Trials for Pain Treatment | DrugBank Online, accessed September 12, 2025, https://go.drugbank.com/drugs/DB00554/clinical_trials?conditions=DBCOND0012160&phase=1&purpose=treatment&status=completed
34. Piroxicam | Side Effects, Dosage, Uses, and More - Healthline, accessed September 12, 2025, https://www.healthline.com/health/drugs/piroxicam-oral-capsule
35. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrAPO-PIROXICAM Piroxicam Capsules Capsules, 10 mg and 20 mg, For Ora, accessed September 12, 2025, https://pdf.hres.ca/dpd_pm/00071325.PDF
36. Piroxicam Capsules - Cleveland Clinic, accessed September 12, 2025, https://my.clevelandclinic.org/health/drugs/18783-piroxicam-capsules
37. Feldene (piroxicam) dosing, indications, interactions, adverse effects, and more, accessed September 12, 2025, https://reference.medscape.com/drug/feldene-piroxicam-343300
38. PIROXICAM CAPSULES USP07560757Rx only - DailyMed, accessed September 12, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1f62485-4f0a-4f7e-b450-62f9ce20f13f&type=display
39. Piroxicam (Systemic) | Drug Lookup | Pediatric Care Online - AAP Publications, accessed September 12, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5549/Piroxicam-Systemic
40. FELDENE - accessdata.fda.gov, accessed September 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018147s033s038s039s040s042lbl.pdf
41. Piroxicam - Arthritis Foundation, accessed September 12, 2025, https://www.arthritis.org/drug-guide/nsaids/piroxicam
42. Piroxicam (Systemic - Memorial Sloan Kettering Cancer Center, accessed September 12, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/piroxicam-systemic
43. Piroxicam: Package Insert / Prescribing Information - Drugs.com, accessed September 12, 2025, https://www.drugs.com/pro/piroxicam.html
44. What is the safety profile of Piroxicam (Nonsteroidal Anti-Inflammatory Drug (NSAID)) in elderly patients? - Dr.Oracle AI, accessed September 12, 2025, https://www.droracle.ai/articles/260812/piroxicam-is-how-much-safe-in-elderly
45. Piroxicam Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 12, 2025, https://www.drugs.com/sfx/piroxicam-side-effects.html
46. www.ncbi.nlm.nih.gov, accessed September 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548425/#:~:text=Piroxicam%20is%20a%20nonsteroidal%20antiinflammatory,be%20severe%20and%20even%20fatal.
47. What are the side effects of Piroxicam? - Patsnap Synapse, accessed September 12, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-piroxicam
48. Piroxicam: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 12, 2025, https://www.rxlist.com/piroxicam/generic-drug.htm
49. Piroxicam Interactions Checker - Drugs.com, accessed September 12, 2025, https://www.drugs.com/drug-interactions/piroxicam.html
50. Feldene Interactions Checker - Drugs.com, accessed September 12, 2025, https://www.drugs.com/drug-interactions/piroxicam,feldene.html
51. Piroxicam Food, Alcohol, Supplements and Drug Interactions - ScriptSave WellRx, accessed September 12, 2025, https://www.wellrx.com/piroxicam/lifestyle-interactions/
52. Piroxicam and Alcohol/Food Interactions - Drugs.com, accessed September 12, 2025, https://www.drugs.com/food-interactions/piroxicam.html
53. A comparative study of efficacy and safety of piroxicam and naproxen in the management of pain in osteoarthritis of the knee | Request PDF - ResearchGate, accessed September 12, 2025, https://www.researchgate.net/publication/325852536_A_comparative_study_of_efficacy_and_safety_of_piroxicam_and_naproxen_in_the_management_of_pain_in_osteoarthritis_of_the_knee
54. Naproxen sodium and piroxicam in acute musculo-skeletal disorders., accessed September 12, 2025, http://bjsm.bmj.com/content/18/2/80
55. Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes - PubMed, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/2454027/
56. Efficacy and safety of piroxicam revisited: a global meta-analysis of randomised clinical trials, accessed September 12, 2025, https://www.ncbi.nlm.nih.gov/books/NBK78103/
57. Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/19467328/
58. Comparison of the Effects of Piroxicam and Diclofenac Sodium as Treatments for Primary Dysmenorrhea - Semantic Scholar, accessed September 12, 2025, https://www.semanticscholar.org/paper/Comparison-of-the-Effects-of-Piroxicam-and-Sodium-Camlibel-Erdur/6b669813b01d7f7111b217a17472b8cd88d742fd
59. Comparison of the Effects of Piroxicam and Diclofenac Sodium as Treatments for Primary Dysmenorrhea - PMC, accessed September 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6330839/
60. Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis, accessed September 12, 2025, https://www.the-rheumatologist.org/article/diclofenac-patch-piroxicam-effective-topical-nsaids-osteoarthritis/
61. Comparing the Effect of Diclofenac Gel and Piroxicam Gel on Mastalgia - ResearchGate, accessed September 12, 2025, https://www.researchgate.net/publication/229576279_Comparing_the_Effect_of_Diclofenac_Gel_and_Piroxicam_Gel_on_Mastalgia
62. A randomized clinical trial comparing ibuprofen to piroxicam for the relief of chronic non-rheumatic joint pain - Scholars@Duke, accessed September 12, 2025, https://scholars.duke.edu/display/pub768834
63. Ibuprofen vs Piroxicam Comparison - Drugs.com, accessed September 12, 2025, https://www.drugs.com/compare/ibuprofen-vs-piroxicam
64. Comparison of the efficacy, safety, and pharmacokinetic profiles of extended-release ketoprofen and piroxicam in patients with rheumatoid arthritis - PubMed, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/8062318/
65. (PDF) Single Blind, Comparative Study of Ketoprofen Cream Vs Diclofenac and Piroxicam Cream in Management of Rheumatoid Arthritis Patients - ResearchGate, accessed September 12, 2025, https://www.researchgate.net/publication/265378550_Single_Blind_Comparative_Study_of_Ketoprofen_Cream_Vs_Diclofenac_and_Piroxicam_Cream_in_Management_of_Rheumatoid_Arthritis_Patients
66. A DOUBLE-BUND STUDY TO COMPARE THE EFFICACY AND SAFETY OF MELOXICAM15 mg WITH PIROXICAM 20 mg IN PATIENTS WITH OSTEOARTHRITIS OF, accessed September 12, 2025, https://academic.oup.com/rheumatology/article-pdf/35/suppl_1/35/5043285/35-suppl_1-35.pdf
67. Celebrex vs Piroxicam Comparison - Drugs.com, accessed September 12, 2025, https://www.drugs.com/compare/celebrex-vs-piroxicam
68. Celecoxib vs Piroxicam Comparison - Drugs.com, accessed September 12, 2025, https://www.drugs.com/compare/celecoxib-vs-piroxicam
69. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis - PubMed, accessed September 12, 2025, https://pubmed.ncbi.nlm.nih.gov/8311540/
70. Management of Osteoarthritis: Expert Opinion on NSAIDs - PMC - PubMed Central, accessed September 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8586433/
71. Generic PIROXICAM INN entry, drug patent expiration information and freedom to operate, accessed September 12, 2025, https://www.drugpatentwatch.com/p/generic/piroxicam
72. Piroxicam Capsules USP, 10 mg and 20 mg. - accessdata.fda.gov, accessed September 12, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207938Orig1s000ltr.pdf
73. Economic Evaluation of the Restriction in the Use of Piroxicam in Spain, accessed September 12, 2025, https://www.reumatologiaclinica.org/en-economic-evaluation-restriction-in-use-articulo-S2173574315000465
74. PSUSA/00002438/202304 - periodic safety update report single assessment, accessed September 12, 2025, https://www.ema.europa.eu/en/medicines/psusa/psusa-00002438-202304
75. Piroxicam (International database) - Drugs.com, accessed September 12, 2025, https://www.drugs.com/international/piroxicam.html